Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus.
Learn MoreWe utilize unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.
Learn MoreOur development programs include a wide variety of serious and/or chronic viral diseases including influenza, COVID-19, hepatitis C and gastroenteritis caused by norovirus.
Learn MoreProgram | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | |
---|---|---|---|---|---|---|
Influenza A | Oral PB2 Inhibitor CC-42344 |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Influenza A | Inhaled PB2 Inhibitor CC-42344 |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase complete
|
Influenza A/B | Replication Inhibitors |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Norovirus & Coronavirus | Oral Pan-viral Protease Inhibitor CDI-988 |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Norovirus | Replication Inhibitors |
Discovery Phase in progress
|
Preclinical Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Respiratory Viruses | Pan-viral Inhibitors |
Discovery Phase in progress
|
Preclinical Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|